CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
colestipol +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000599
NCT00000599Phase 3Completed
CompareCT.gov

Cholesterol-Lowering Atherosclerosis Study (CLAS)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Dec 13, 2013

In Brief

A Phase 3 clinical trial evaluating colestipol, niacin, and 1 other intervention for Arterial Occlusive Diseases and 9 related conditions. Completed.

Detailed Summary

To determine whether combined therapy with the lipid lowering agents colestipol hydrochloride plus niacin would produce significant change in coronary, carotid, and femoral artery atherosclerosis and coronary bypass graft lesions as determined by angiography. Also, to determine possible correlations between lesion changes and plasma lipid and lipoprotein cholesterol levels and to explore interrelationships of atherosclerosis change in femoral, coronary, and carotid arteries.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArterial Occlusive Diseases, Cardiovascular Diseases, Carotid Artery Diseases, Cerebral Arteriosclerosis, Cerebrovascular Disorders, Coronary Arteriosclerosis, Coronary Disease, Heart Diseases, Myocardial Ischemia, Atherosclerosis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartJun 1, 1980
Study CompletionNov 1, 1994
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

colestipoldrug

niacindrug

diet, fat-restrictedbehavioral